Adam Zamecnik
Reporter
Adam has previously worked at GlobalData Media as a Healthcare Reporter, writing longer and shorter articles for the public website Pharmaceutical Technology and the Pharma Intelligence Centre. During his time there, Adam focused on topics such as cell and gene therapy, vaccine research, and new approaches to the treatment of haematological conditions. He has also covered the development of new biosimilars, the production of complex generics, and legal battles between Big Pharma. Prior to this, Adam wrote as a freelance reporter for the likes of Vice World News. Adam holds an MA in International Journalism from City, University of London.
Latest From Adam Zamecnik
Hyloris Follows On Transaction Scrutiny With Maxigesic IV Updates
Following its recently announced leadership changes, Hyloris has made two announcements linked to the marketing of its combined pain therapy Maxigesic IV in Brazil and the US.
ANI Announces Final US Approval And Launch Of Endari Generic
Despite doubling down on its rare disease ambitions with its Alimera acquisition earlier in July, ANI just announced the second US launch of a generic this month.
Amneal Launches Polysorbate-Free Fosaprepitant In The US
Marking the firm’s second launch of a 505(b)(2) injectable this year, Amneal has released Focinvez in the US as an antiemetic agent used in chemotherapy regimens.
Hikma Launches First US Sodium Acetate With CGT Exclusivity
Following on from a flurry of deal and launches, Hikma has released another product onto the US market with the first of its sodium acetate injections, bolstered by 180 days of Competitive Generic Therapy exclusivity.
Hyloris Replaces Leadership After Continued Transaction Woes
Marking a further development in the story of Hyloris’ in-licensing deal with QliniQ, the company’s board has announced significant leadership and organizational changes to address potential concerns.
ANI Acquires Alimera Sciences To Bolster Ophthalmology Portfolio
ANI has acquired Alimera Sciences in a move to expand its rare disease business, highlighting its increasing drift from generics.